TrovaGene and NewLink Genetics Find Investors Optimistic About Products

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / TrovaGene and NewLink Genetics stock rose in Thursday’s trading session as both companies caught the attention of investors after optimism about their current FDA Phase progress.

RDI Initiates
Coverage:

TrovaGene Inc. https://ub.rdinvesting.com/news/?ticker=TROV

NewLink Genetics
Corp. https://ub.rdinvesting.com/news/?ticker=NLNK

TrovaGene advanced 9.52% to close at $1.15 on Thursday. The stock traded between $1.15 and $1.05 on volume of 171,426 178,012 shares traded. The company, a biotechnology company, develops oncology therapeutics for improved cancer care, announced that it is to present at the MicroCap Conference to be held on April 4, 2017 in New York City.

In its 4th quarter financial report, the company showed a net loss of $8.5 million or $0.34 per diluted share, which has narrowed down significantly from net loss of $10.2 million reported in the 3rd quarter of 2016, but is higher than the loss of $7.4 million reported in the fourth quarter of 2015. Operations had the biggest drag on the company bottom line, as they increased to nearly $9.9 million from $7.5 million of the same period of report in 2015. At the end of December 31, 2016, Trovagene had approximately $37.9 million in cash assets available for operations.

Access RDI’s TrovaGene Research Report at: https://ub.rdinvesting.com/news/?ticker=TROV

NewLink Genetics advanced 5.62% to close at $23.12 on Thursday. The stock traded between $24.85 and $22.835 on a volume of 1.06 million shares traded. The surge in price came after Peter Lawson of SunTrust Robinson Humphrey upgraded the company from “hold” to “buy” and raised the price target to $30 from a previous target of $12, and expressed his view that NewLink is “well positioned” to become a potential takeover target. Potential positive news from ongoing product trials after having gone through a major setback earlier. The company’s IDO-inhibitor space therapies target cancer patients, and NewLink has a unique position as it is virtually alone in its pursuit of IDO-inhibitor solutions.

Newlink has a mix of “buy” and “hold” ratings from small numbers of investment research firms, with consensus ratings as “overweight” and Thursday’s advances has resulted in the stock to went rising more than 120% in 2017.

Access RDI’s NewLink Genetics Research Report at: https://ub.rdinvesting.com/news/?ticker=NLNK

Our Actionable Research on TrovaGene Inc. (NASDAQ: TROV) and NewLink Genetics Corp. (NASDAQ: NLNK) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458650